Genomically effective dose.

You remember GARD, genomically adjusted radiation dose, taking the concept of biologically effective dosing to the next level with tumor genomics. Here’s its largest test to date, a pooled analysis of 1615 patients with one of seven various primary tumor sites. Indeed, diminishing GARD was associated with diminishing survival and disease control in a continuous manner, while physical radiation dose was not. This could mean a paradigm shift to tumor genomics guiding not only what but how much therapy is beneficial. | Scott, medRxiv 2021